Identification of SNPs associated with methotrexate treatment outcomes in patients with early rheumatoid arthritis

Identification of SNPs associated with methotrexate treatment outcomes in patients with early rheumatoid arthritis

Methotrexate is one of the cornerstones of rheumatoid arthritis (RA) therapy. Genetic factors or single nucleotide polymorphisms (SNPs) are responsible for 15%–30% of the variation in drug response. Identification of clinically effective SNP biomarkers for predicting methotrexate (MTX) sensitivity h...

Full description

Bibliographic Details
Main Authors: Shrikant S. Kolan, Gaoyang Li, Franco Grimolizzi, Joe Sexton, Guro Goll, Tore K. Kvien, Nina Paulshus Sundlisæter, Manuela Zucknick, Siri Lillegraven, Espen A. Haavardsholm, Bjørn Steen Skålhegg
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-11-01
Series:Frontiers in Pharmacology
Subjects:
methotexate
rheumatoid arthritis
single nucelotide polymorphisms
clincal outcomes
association
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.1075603/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.1075603/full

Similar Items